Diabetic Maculopathy
11
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Aflibercept and Bevacizumab for Diabetic Maculopathies
Is Community Based Monitoring of Diabetic Maculopathy and Pre-proliferative Diabetic Retinopathy Safe?
Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM
Discovering Early Biomarkers in Circulating Endothelial Cells for Diabetes Complications by Single Cell RNA Sequencing
Retinal Oximtery Following Treatment for Diabetic Maculopathy
Non-Responsive Diabetic Macular Edema and Spironolactone
Reading Analysis in Ophthalmologic Patients
Diameter Changes of Retinal Vessels During Hypoxia
Shanghai Beixinjing Diabetic Eyes Study
Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography
Selective RPE Laser Treatment (SRT) for Various Macular Diseases